论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Liu W, Hu J, Zhou K, Chen F, Wang Z, Liao B, Dai Z, Cao Y, Fan J, Zhou J
Received 20 April 2017
Accepted for publication 13 June 2017
Published 1 August 2017 Volume 2017:10 Pages 3843—3851
DOI https://doi.org/10.2147/OTT.S140062
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Geoffrey Pietersz
Abstract: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide
with high mortality. Circulating miRNA has been demonstrated as a novel noninvasive
biomarker for many tumors. This study aimed to investigate the potential of
circulating miR-125b as a prognostic marker of HCC. Exosomes were extracted
from serum samples collected from two independent cohorts: cohort 1: HCC
(n=30), chronic hepatitis B (CHB, n=30), liver cirrhosis (LC, n=30); cohort 2:
HCC (n=128). We found that miR-125b levels were remarkably increased in
exosomes compared to those in serum from patients with CHB, LC, and HCC (P <0.01, respectively). However,
miR-125b levels in exosomes and the serum from HCC patients were inferior to
that of CHB (P <0.01 and P =0.06) and LC patients (P <0.01 for all). Additionally,
miR-125b levels in exosomes were associated with tumor number (P =0.02), encapsulation (P <0.01), and TNM stage (P <0.01). Kaplan–Meier analysis
indicated that HCC patients with lower exosomal miR-125b levels showed reduced
time to recurrence (TTR) (P <0.01) and
overall survival (OS) (P <0.01).
Furthermore, multivariate analysis revealed that miR-125b level in exosomes,
but not in serum, was an independent predictive factor for TTR (P <0.001) and OS (P =0.011). Exosomal miR-125b levels
predicted the recurrence and survival of HCC patients with an area under the
ROC curve of 0.739 (83.0% sensitivity and 67.9% specificity) and 0.702 (82.5%
sensitivity and 53.4% specificity). In conclusion, exosomal miR-125b could
serve as a promising prognostic marker for HCC.
Keywords: exosome,
miR-125b, hepatocellular carcinoma, prognosis, serum